Skip to main content
In The News

A Letter From Our CEO

By September 6, 2023No Comments
Carevive achieved significant milestones in the first half of 2023.

Carevive achieved significant milestones in the first half of 2023.

We completed the successful launch of the STAIRS™ cancer symptom management pathways, a project that spanned five years and was supported by a multi-million-dollar research contract from the National Cancer Institute (NCI). Furthermore, we enhanced accessibility to our platform by introducing a Spanish version of our remote patient monitoring workflow, making sure that every cancer patient, irrespective of their language, has access to the same benefit by elevating the patient’s perspective in cancer care in a fair and consistent manner. Having a native mobile app option increases accessibility and usability which means patients are more likely to respond, leading to better outcomes and increased patient satisfaction.

We are committed to innovating our product development efforts to further advance health equity, enhance accessibility, and facilitate remote patient management.

Our Life Science division experienced remarkable growth, expanding its cancer registry data offerings, and forming partnerships with pharmaceutical companies to provide insights across a wide range of cancer types and therapies.

We published at major conferences (ASCO, ISPOR) and developed “Invaluable Insights,” a compilation of publications, presentations, and posters that outline our research on utilizing digital tools and data to create a positive impact on the care and outcomes of patients with cancer. Download your free copy here!

Within our Provider business, we extended our reach across various Cancer Center segments, effectively addressing diverse requirements through technological solutions and expert knowledge. Our dedication to value-based care and reimbursement models was solidified through active engagement in industry conferences.

In addition to these achievements, Carevive undertook a variety of projects, including the redesign of PROmpt Patient Assets; a successful symptom pathways tool, STAIRS™, featuring video testimonials; technological advancements; research site training; implementation kickoffs; inventive strategies; and numerous on-site visits.

Overall, these activities represent a dynamic scope of projects and accomplishments, serving as a testament to our commitment to excellence and advancement in patient care across various domains within our organization.

We are grateful and value our partners as we move forward in the second half of 2023.


Bruno Lempernesse
Chief Executive Officer